IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tejedor, J.
Right arrow Articles by Rodríguez, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tejedor, J.
Right arrow Articles by Rodríguez, J. M.
(Investigative Ophthalmology and Visual Science. 2001;42:2542-2546.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Long-Term Outcome and Predictor Variables in the Treatment of Acquired Esotropia with Botulinum Toxin

Jaime Tejedor and José M. Rodríguez

From the Department of Ophthalmology, Hospital Ramón y Cajal, Madrid, Spain.

PURPOSE. To determine the long-term results of botulinum therapy in acquired esotropia and to identify predictors of a satisfactory outcome.

METHODS. Sixty-eight children (age range, 8–64 months) with acquired esotropia were enrolled in a prospective study. Botulinum toxin A was injected in the two medial recti. Motor and sensory statuses were evaluated at 1 and 2 weeks; 3, 6, and 12 months; and every year after the last injection. Univariate and multivariate logistic regression analyses were performed to relate motor and sensory outcome to variables recorded as potential predictors.

RESULTS. After an average follow-up of 4.8 years since the last injection, motor success was obtained in 36 children with one injection (52.9%), increasing to 48 (70.6%) and 60 (88.2%) children after two and three injections, respectively. Forty-eight (70.6%) patients had at least peripheral fusion (category 1 binocularity) and 32 (47.1%) had stereoacuity of at least 400 seconds of arc (category 2 binocularity). Higher hypermetropia, less severe amblyopia, and a smaller angle of esotropia were the best predictors of motor success. Minimal amblyopia and favorable motor alignment were associated with better binocularity outcome.

CONCLUSIONS. Botulinum is an effective long-term treatment of acquired esotropia. It is especially useful in children with high hypermetropia, minimal amblyopia, and small esotropic deviation.




This article has been cited by other articles:


Home page
Arch OphthalmolHome page
J. Tejedor and J. M. Rodriguez
Management of Nonresolving Consecutive Exotropia Following Botulinum Toxin Treatment of Childhood Esotropia
Arch Ophthalmol, September 1, 2007; 125(9): 1210 - 1213.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology